Clinical Trials Logo

Carcinoma, Basal Cell clinical trials

View clinical trials related to Carcinoma, Basal Cell.

Filter by:

NCT ID: NCT03483441 Recruiting - Clinical trials for Basal Cell Carcinoma

Vitamin D and Photodynamic Therapy for Treatment of BCC in BCNS

Start date: October 1, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this research is to evaluate the use of Photodynamic Therapy (PDT) to treat the multiple basal cell carcinoma (BCC) skin cancers in children and adults with Basal Cell Nevus Syndrome (or who have at least 3 BCC tumors present). In addition, the investigators will test a hypothesis (based upon our extensive preclinical studies in mice) that induction of a transient spike in serum Vitamin D levels through administration of dietary Vitamin D (cholecalciferol; D3) can significantly increase PDT efficacy and improve the clearance of cutaneous BCC tumors.

NCT ID: NCT03370861 Recruiting - Melanoma Clinical Trials

How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes

MINING
Start date: November 8, 2017
Phase:
Study type: Observational

The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy.

NCT ID: NCT03210935 Recruiting - Clinical trials for Merkel Cell Carcinoma

French National Database of Rare Dermatological Cancers

CARADERM
Start date: November 24, 2015
Phase:
Study type: Observational

Merkel cell carcinoma, advanced basal cell carcinoma requiring systemic treatment, and cutaneous adnexal carcinomas are 3 types of rare skin cancers for which much remains unknown in terms of natural behavior, prognosis, treatment and outcomes. CARADERM is a French prospective national cohort enrolling patients with either one of these 3 tumor types, whose objectives are : - to provide epidemiological, clinical and socio-economic characteristics of patients - to identify new clinical or epidemiological prognostic factors for these rare cancers - to evaluate the impact of various treatments on outcomes

NCT ID: NCT03092830 Recruiting - Clinical trials for Squamous Cell Carcinoma

Molecular Characterization of Cutaneous Tumors

Start date: March 29, 2017
Phase:
Study type: Observational

The objective is to find genes which are responsible for the appearance of skin tumors (sCC, BCC) and it will be the basis for prediction of the disease and response to the treatment

NCT ID: NCT03069846 Recruiting - Skin Cancer Clinical Trials

Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope

Start date: June 5, 2017
Phase: N/A
Study type: Interventional

The primary objective is to collect emission spectra of normal tissue, pigmented normal lesion, benign lesion, SCC, BCC and melanoma to construct the database and validate the classifying algorithm.

NCT ID: NCT03050268 Recruiting - Pancreatic Cancer Clinical Trials

Familial Investigations of Childhood Cancer Predisposition

SJFAMILY
Start date: April 6, 2017
Phase:
Study type: Observational

NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown in the Eligibility Section, you may enroll regardless of the results of your clinical genetic testing. While it is well recognized that hereditary factors contribute to the development of a subset of human cancers, the cause for many cancers remains unknown. The application of next generation sequencing (NGS) technologies has expanded knowledge in the field of hereditary cancer predisposition. Currently, more than 100 cancer predisposing genes have been identified, and it is now estimated that approximately 10% of all cancer patients have an underlying genetic predisposition. The purpose of this protocol is to identify novel cancer predisposing genes and/or genetic variants. For this study, the investigators will establish a Data Registry linked to a Repository of biological samples. Health information, blood samples and occasionally leftover tumor samples will be collected from individuals with familial cancer. The investigators will use NGS approaches to find changes in genes that may be important in the development of familial cancer. The information gained from this study may provide new and better ways to diagnose and care for people with hereditary cancer. PRIMARY OBJECTIVE: - Establish a registry of families with clustering of cancer in which clinical data are linked to a repository of cryopreserved blood cells, germline DNA, and tumor tissues from the proband and other family members. SECONDARY OBJECTIVE: - Identify novel cancer predisposing genes and/or genetic variants in families with clustering of cancer for which the underlying genetic basis is unknown.

NCT ID: NCT01633515 Recruiting - Clinical trials for Basal Cell Carcinoma (BCC)

Intralesional Cryosurgery for Basal Cell Carcinoma - a Feasibility Study

Start date: July 2012
Phase: N/A
Study type: Interventional

A feasibility study for the treatment of Basal Cell Carcinoma of the lower extremities in the elderly utilizing intralesional cryosurgery. 10 cases of BCC (confirmed by biopsy) in the lower extremity of elderly will undergo intralesional cryotherapy. A Cryoneedle is introduced through the skin lesion (BCC) and thus the BCC is frozen. Treatment success will be determined according to biopsy results 3 months after treatment

NCT ID: NCT01491711 Recruiting - Clinical trials for Superficial Basal Cell Carcinoma

Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate

Start date: August 2013
Phase: Phase 4
Study type: Interventional

Skin cancer is the most common cancer in Caucasians, and a basal cell carcinoma (BCC) being the most common skin cancer with around 44,000 new tumours per year, and its incidence is still rising. In the past it has been a disease of the elderly patient but as a consequence of recreational sun exposure and tanning beds, more young patients develop a skin cancer as well. There are different subtypes of BCC and most subtypes are treated by surgical excision. Nowadays, non-invasive techniques as photodynamic therapy (PDT) are common practice to treat superficial BCC (sBCC). Because of these techniques treatment by surgical excision can be avoided with the possibility of complications and scar formation. Both 5-aminolevulino acid (5-ALA) and the more lipophilic methyl aminolevulinate (MAL) can be used as a precursor of the photosensitiser. These agents generate an excess of protoporphyrin IX in metabolic active cells, which are illuminated by a specific light source leading to release of reactive oxygen radicals in tissue. The result is apoptosis and necrosis of tumour cells. At the moment, two treatment protocols are used in the Netherlands: the fractionated 5-ALA 20% (Fagron) protocol according to de Haas and the MAL (Metvix, Galderma) protocol. Because MAL was first marketed and registered as a treatment option for premalignant and superficial malignancies most hospitals in the Netherlands use this topical agent. However, there is no evidence which of the 2 agents is more (cost-)effective and/ or preferred by patients. Objective: to determine which treatment is the most effective treatment in terms of prevention of treatment failure, cost saving and patients preference when comparing fractionated 5-ALA 20% PDT versus MAL PDT in 2 treatment sessions.

NCT ID: NCT01349361 Recruiting - Clinical trials for Photodynamic Therapy

Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight

Start date: March 2011
Phase: Phase 2
Study type: Interventional

Photodynamic Therapy (PDT) is an effective treatment of basal cell carcinomas (BCC) however the inconvenience of clinic attendance and discomfort during therapy are significant drawbacks. The objective of this study is to evaluate the effect of daylight-mediated PDT of BCC.

NCT ID: NCT00803907 Recruiting - Clinical trials for Carcinoma, Basal Cell

Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma

Imiquimod
Start date: December 2008
Phase: Phase 4
Study type: Interventional

This study aimed to prove the efficacy and safety of the use of imiquimod 5% cream in the periorbital region.